**Table S1** Cells were cultured in the indicated medium

| Cell line     | Culture  | Additive                          |
|---------------|----------|-----------------------------------|
| MDA-MB-231    | L15      |                                   |
| SKBR3         | McCoy’s 5A | na                            |
| BT474         | RPMI-1640 | na                              |
| HS578T        | HG DMEM  | 0.01 mg/mL insulin              |
| MCF7          | HG DMEM  | 0.01 mg/mL insulin              |
| BT549         | RPMI-1640 | 0.01 mg/mL insulin             |
| MCF10A        | DMEM/F12 | 0.01 mg/mL insulin, 2-ng/mL rhEGF, 0.4-μg/mL hydrocortisone |

HG DMEM, high-glucose Dulbecco’s modified Eagle medium; na, not applicable; rhEGF, recombinant human epidermal growth factor.

RhEGF and insulin were purchased from Solarbio (Beijing, China). All culture media were purchased from HyClone (Utah, USA), and Lipofectamine 2000 and Opti-MEM were obtained from Invitrogen (Thermo Fisher Scientific, CA, USA).
Supplemental Digital Content 2

**Antibodies**

The following antibodies were used: TRIM72 (1:1,000, ProteinTech, Chicago, IL, USA), PPP3CA (1:1,000, ProteinTech), lactate dehydrogenase A (LDHA) (1:1,000, ProteinTech), GAPDH (1:10,000, Kangcheng-Medical Co., Ltd., Shanghai, China), and PI3K/Akt/mTOR pathway-related molecules (i.e., p-PI3K (1:1,000, Bioss, Inc., Beijing, China), PI3K (1:1,000, Bioss, Inc.), p-Akt (1:1,000, ProteinTech), Akt (1:1,000, ProteinTech), p-mTOR (1:1,000, Bioss, Inc.), and mTOR (1:1,000, ProteinTech), and peroxidase-rabbit anti-goat immunoglobulin G (IgG) (1:3,000, BOSHIDE Biological Engineering Co., Ltd., Wuhan, China) and peroxidase-rabbit anti-rat IgG (1:2,000, BOSHIDE Biological Engineering Co.).